Pacira Pharmaceuticals Inc (PCRX)

Receivables turnover

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Revenue (ttm) US$ in thousands 638,707 621,403 618,553 613,360 627,091 646,604 609,214 577,203 541,534 491,997 489,092 436,030 429,647 421,097 408,298 435,397 421,026 393,717 372,480 353,983
Receivables US$ in thousands 105,556 96,956 99,079 93,205 98,397 93,471 91,105 92,103 96,318 49,975 68,357 52,583 53,046 46,143 44,013 38,988 47,530 42,573 41,147 39,766
Receivables turnover 6.05 6.41 6.24 6.58 6.37 6.92 6.69 6.27 5.62 9.84 7.15 8.29 8.10 9.13 9.28 11.17 8.86 9.25 9.05 8.90

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $638,707K ÷ $105,556K
= 6.05

To analyze Pacira BioSciences Inc's receivables turnover, we can calculate the average receivables turnover based on the values provided in the table.

Average Receivables Turnover = (6.39 + 6.87 + 6.75 + 7.18 + 6.78 + 7.00 + 6.74 + 6.30) / 8
Average Receivables Turnover = 6.75

The average receivables turnover for Pacira BioSciences Inc over the past 8 quarters is 6.75. This indicates that, on average, the company is able to convert its accounts receivable into cash approximately 6.75 times within a given period. A higher receivables turnover is generally favorable as it suggests that the company is efficient in collecting payments from its customers.

Analyzing the trend, we see that the receivables turnover has been relatively stable around the average value of 6.75 over the quarters. This consistency may indicate a consistent and effective credit management and collection process within the company.

It is important to consider industry benchmarks and compare Pacira BioSciences Inc's receivables turnover with its peers to gain further insights into the company's performance in managing its accounts receivable.